Press Releases

Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness NUTLEY, N.J., Aug. 17, 2023 /PRNewswire/ -- Eisai Inc., the United States-based pharmaceutical subsidiary of Eisai...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the...

State-of-the-art Eisai US hhceco Center underscores New Jersey as the premier life science hub NUTLEY, N.J., Aug. 18, 2022 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai...

Thomas D. Fagan Jr. Appointed Vice President, U.S. Alzheimer's Disease Commercial at Eisai Inc. NUTLEY, N.J., July 27, 2022 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the expansion of its leadership team to include Tricia Brooks as Vice President & Head of Office, Government...

Eisai today announced that H3 Biomedicine (H3), its cancer genomics-based drug discovery subsidiary company located in Cambridge, Mass., has appointed a new executive leadership team. Ping Zhu,...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointment of Janna Hutz, Ph.D., as President of the Eisai Center for Genetics Guided Dementia Discovery...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Andree Amelsberg, M.D., MBA, as Vice President, U.S. Medical Affairs, Oncology...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its animation “Leave No One Behind－Disease of Neglected People” which features activities for the...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. and BioLabs announced today the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups aiming...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been listed in the 2021 Global 100 Most Sustainable Corporations in the World (Global 100), a...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Dr. Richard Woodman as Chief Clinical Officer (CCLO) of its Oncology Business Group....

LOS ANGELES – (BUSINESS WIRE)--Global Coalition for Adaptive Research (LOS ANGELES, CA), Amgen (THOUSAND OAKS, CA), and Eisai Co., Ltd. (TOKYO, Japan “Eisai”) -- The Global Coalition for...

Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., (based in Tokyo, Japan) announced today the relocation of its New Jersey-based...

As Eisai Inc. continues to bring innovative medicines and dynamic solutions to the marketplace, the company announces today the expansion of its leadership team to include two key appointments in...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that it has been selected as the highest rated company “A” in the Climate Change Report 2019 issued by the...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Priya Chaturvedi, Ph.D., as Vice President, Global Clinical Quality Assurance. Dr....

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Patrick Coyle as Vice President and Chief Financial Officer (CFO). In this role, Mr....

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Adriana Herrera as Senior Vice President, Americas Commercial Oncology. Herrera will...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Dr. Luca Dezzani as Vice President, U.S. Medical Affairs, Oncology Business Group....

In its relentless pursuit to develop medications that will address the entire scope of Alzheimer's disease (AD), Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Stephen Davies as Vice President, Eisai Strategic Information Systems. Mr. Davies...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will launch the Eisai Center for Genetics Guided Dementia Discovery, which will harness the power of human...

Eisai Inc. announced today the appointment of Lihua Yu, Ph.D., to President & Chief Data Sciences Officer, H3 Biomedicine, the cancer genomics based drug discovery company of Eisai. In her new...

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., today announced that it has signed an agreement with Grupo Biotoscana (GBT) granting GBT the exclusive...